WALDENSTROM’S MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA (Page 10)

REFERENCES

1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenström’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström’s macroglobulinemia. Semin Oncol 2003; 30:110–15.
2. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361–92.
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10:1419–32.
4. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenström’s macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer 1998; 82:1078–81.
5. Herrinton LJ, Weiss NS. Incidence of Waldenström’s macroglobulinemia. Blood 1993; 82:3148–50.
6. Bjornsson OG, Arnason A, Gudmunosson S, Jensson O, Olafsson S, Valimarsson H. Macroglobulinaemia in an Icelandic family. Acta Med Scand 1978; 203:283–8.
7. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenstrom’s Macroglobulinemia. Ann Oncol 2006; 17: 488-94.
8. Renier G, Ifrah N, Chevailler A, Saint-Andre JP, Boasson M, Hurez D. Four brothers with Waldenström’s macroglobulinemia. Cancer 1989; 64:1554–9.
9. Ogmundsdottir HM , Sveinsdottir S, Sigfusson A, Skaftadottir I, Jonasson JG, Agnarsson BA. Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2. Clin Exp Immunol 1999; 117:252–60.
10. Linet MS, Humphrey RL, Mehl ES, Brown LM, Pottern LM, Bias WB, et al. A case-control and family study of Waldenström’s macroglobulinemia. Leukemia 1993; 7:1363–9.
11. Santini GF, Crovatto M, Modolo ML, Martelli P, Silvia C, Mazzi G, et al. Waldenström macroglobulinemia: a role of HCV infection? Blood 1993; 82:2932.
12. Silvestri F, Barillari G, Fanin R, Zaja F, Infanti L, Patriarca F, et al. Risk of hepatitis C virus infection, Waldenström’s macroglobulinemia, and monoclonal gammopathies. Blood 1996; 88:1125–6.
13. Leleu X, O’Connor K, Ho A, Santos DD, Manning R, Xu L, Hatjiharissi E, Tournilhac O, Chemaly M, Branagan AR, Hunter ZR, Patterson CJ, Anderson KC, and Treon, SP. Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia. Am J Hematol 2006. Am J Hematol 2007; 82: 83-4.
14. Carbone P, Caradonna F, Granata G, Marceno R, Cavallaro AM, Barbata G Chromosomal abnormalities in Waldenstrom's macroglobulinemia. Cancer Genet Cytogenet. 1992; 61:147-51.
15. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 2001; 116:543–9.
16. Han T, Sadamori N, Takeuchi J, Ozer H, Henderson ES, Bhargava A, Fitzpatrick J, Sandberg AA. Clonal chromosome abnormalities in patients with Waldenstrom's and CLL-associated macroglobulinemia: significance of trisomy 12. Blood 1983; 62:525-31.
17. Rivera AI, Li MM, Beltran G, Krause JR. Trisomy 4 as the sole cytogenetic abnormality in a Waldenstrom macroglobulinemia. Cancer Genet Cytogenet. 2002; 133:172-3.
18. Wong KF, So CC, Chan JC, Kho BC, Chan JK. Gain of chromosome 3/3q in B-cell chronic lymphoproliferative disorder is associated with plasmacytoid differentiation with or without IgM overproduction. Cancer Genet Cytogenet. 2002; 136:82-5.
19. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100:2996–3001.
20. Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenstrom’s macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007; 136: 80-6.
21. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenstrom’s macroglobulinemia. Proceedings of the 5^th International Workshop on Waldenstrom’s macroglobulinemia, Stockholm, Sweden 2008 (Abstract 125).
22. Leleu X, Hunter ZR, Xu L, et al. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia Br J Haematol 2009; 145: 59-63.
23. Avet-Loiseau H, Garand R, Lode L, Robillard N, Bataille R. 14q32 translocations discriminate IgM multiple myeloma from Waldenstrom’s macroglobulinemia. Semin Oncol 2003; 30:153-155.
24. Preud’homme JL, Seligmann M. Immunoglobulins on the surface of lymphoid cells in Waldenström’s macroglobulinemia. J Clin Invest 1972; 51:701–5.
25. Smith BR, Robert NJ, Ault KA. In Waldenstrom’s macroglobulinemia the quantity of detectable circulating monoclonal B lymphocytes correlates with clinical course. Blood 1983; 61:911–14.
26. Levy Y, Fermand JP, Navarro S, Schmitt C, Vainchenker W, Seligmann M, et al. Interleukin 6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammopathy. Proc Natl Acad Sci USA 1990; 87:3309–13.
27. Owen RG, Barrans SL, Richards SJ, O’Connor SJ, Child JA, Parapia LA, Morgan GJ, et al. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420–8.
28. Feiner HD, Rizk CC, Finfer MD, Bannan M, Gottesman SR, Chuba JV, et al. IgM monoclonal gammopathy/Waldenström’s macroglobulinemia: a morphological and immunophenotypic study of the bone marrow. Mod Pathol 1990; 3:348–56.
29. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia. Semin Oncol 2003; 30:187-95.
30. Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, Treon SP, CD5, CD10, CD23 expression in Waldenstrom’s Macroglobulinemia. Clin Lymph 2005; 5:246-9.
31. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenström’s macroglobulinemia, and myeloma. Blood 1994; 83:3647–53.
32. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström’s macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter’s syndrome but not in common CLL. Blood 1995; 85:1913–19.
33. Shiokawa S, Suehiro Y, Uike N, Muta K, Nishimura J. Sequence and expression analyses of mu and delta transcripts in patients with Waldenström’s macroglobulinemia. Am J Hematol 2001; 68:139–43.
34. Sahota SS, Forconi F, Ottensmeier CH, Provan D, Oscier DG, Hamblin TJ, et al. Typical Waldenström macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100:1505–7.
35. Paramithiotis E, Cooper MD. Memory B lymphocytes migrate to bone marrow in humans. Proc Natl Acad Sci USA 1997; 94:208–12.
36. Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP. Mast cells in Waldenstrom’s Macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17: 1275-82.
37. Ho A., Leleu X., Hatjiharissi E., Tournilhac O., Xu L., O’Connor K., Manning R., Santos D., Chemaly M., Branagan A., Hunter Z., Patterson, Anderson KC., Treon S. CD27-CD70 interactions in the pathogenesis of Waldenstrom’s Macroglobulinemia. Blood 2008; 112:4683-9.
38. Merlini G, Farhangi M, Osserman EF. Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. Semin Oncol 1986; 13:350–65.
39. Farhangi M, Merlini G. The clinical implications of monoclonal immunoglobulins. Semin Oncol 1986; 13:366–79.
40. Marmont AM, Merlini G. Monoclonal autoimmunity in hematology. Haematologica 1991; 76:449–59.
41. Mackenzie MR, Babcock J. Studies of the hyperviscosity syndrome. II. Macroglobulinemia. J Lab Clin Med 1975; 85:227–34.
42. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intens Care Med 1995; 10:128–41.
43. Kwaan HC, Bongu A. The Hyperviscosity syndromes. Semin Thromb Hemost 1999; 25:199–208.
44. Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993; 91:251–6.
45. Menke MN, Feke GT, McMeel JW, Branagan A, Hunter Z, Treon SP. Hyperviscosity-related retinopathy in Waldenstrom’s Macroglobulinemia. Arch Opthalmol 2006; 124: 1601-6.
46. Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, et al. Prognostic factors in symptomatic Waldenström’s macroglobulinemia. Semin Oncol 2003; 30:211–15.
47. Dellagi K, Dupouey P, Brouet JC, Billecocq A, Gomez D, Clauvel JP, et al. Waldenström’s macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood 1983; 62:280–5.
48. Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987; 37:1506–14.
49. Nemni R, Gerosa E, Piccolo G, Merlini G. Neuropathies associated with monoclonal gammapathies. Haematologica 1994; 79:557–66.
50. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338:1601–7.
51. Vital A. Paraproteinemic neuropathies. Brain Pathol 2001; 11:399–407.
52. Latov N, Braun PE, Gross RB, Sherman WH, Penn AS, Chess L. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci USA 1981; 78:7139–42.
53. Chassande B, Leger JM, Younes-Chennoufi AB, Bengoufa D, Maisonobe T, Bouche P, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998; 21:55–62.
54. Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol 1999; 95:174–84.
55. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988; 3:301–32.
56. Dalakas MC, Quarles RH. Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens? Ann Neurol 1996; 39:419–22.
57. Eurelings M, Ang CW, Notermans NC, Van Doorn PA, Jacobs BC, Van den Berg LH. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 2001; 57:1909–12.
58. Ilyas AA, Quarles RH, Dalakas MC, Fishman PH, Brady RO. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985; 18:655–9.
59. Willison HJ, O’Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124:1968–77.
60. Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 2002; 25:828–36.
61. Jacobs BC, O’Hanlon GM, Breedland EG, Veitch J, Van Doorn PA, Willison HJ. Human IgM paraproteins demonstrate shared reactivity between Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides. J Neuroimmunol 1997; 80:23–30.
62. Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of antineural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36:416–24.
63. Gordon PH, Rowland LP, Younger DS, Sherman WH, Hays AP, Louis ED, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 1997; 48:1671–8.
64. Pavord SR, Murphy PT, Mitchell VE. POEMS syndrome and Waldenström’s macroglobulinaemia. J Clin Pathol 1996; 49:181–2.
65. Crisp D, Pruzanski W. B–cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 1982; 72:915–22.
66.  Pruzanski W, Shumak KH. Biologic activity of cold-reacting autoantibodies (first of two parts). N Engl J Med 1977; 297:538–42.
67. Pruzanski W, Shumak KH. Biologic activity of cold-reacting autoantibodies (second of two parts). N Engl J Med 1977; 297:583–9.
68. Whittaker SJ, Bhogal BS, Black MM. Acquired immunobullous disease: a cutaneous manifestation of IgM macroglobulinaemia. Br J Dermatol 1996; 135:283–6.
69. Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol 1999; 40:507–35.
70. Gad A, Willen R, Carlen B, Gyland F, Wickander M. Duodenal involvement in Waldenström’s macroglobulinemia. J Clin Gastroenterol 1995; 20:174–6.
71. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1990. A 66-year-old woman with Waldenström’s macroglobulinemia, diarrhea, anemia, and persistent gastrointestinal bleeding. N Engl J Med 1990; 322:183–92.
72. Isaac J, Herrera GA. Cast nephropathy in a case of Waldenström’s macroglobulinemia. Nephron 2002; 91:512–15.
73. Morel-Maroger L, Basch A, Danon F, Verroust P, Richet G. Pathology of the kidney in Waldenström’s macroglobulinemia. Study of sixteen cases. N Engl J Med 1970; 283:123–9.
74. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström’s macroglobulinemia. J Clin Oncol 1993; 11:914–20.
75. Moyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino acid residues) amyloid fibril protein AA from a patient with Waldenström’s macroglobulinaemia and amyloidosis. Scand J Immunol 1980; 11:549–54.
76. Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM. Waldenström’s macroglobulinemia associated with AA amyloidosis. Int J Hematol 2001; 74:76–8.
77. Dussol B, Kaplanski G, Daniel L, Brunet P, Pellissier JF, Berland Y. Simultaneous occurrence of fibrillary glomerulopathy and AL amyloid. Nephrol Dial Transplant 1998; 13:2630–2.
78. Rausch PG, Herion JC. Pulmonary manifestations of Waldenström macroglobulinemia. Am J Hematol 1980; 9:201–9.
79. Fadil A, Taylor DE. The lung and Waldenström’s macroglobulinemia. South Med J 1998; 91:681–5.
80. Kyrtsonis MC, Angelopoulou MK, Kontopidou FN, Siakantaris MP, Dimopoulou MN, Mitropoulos F, et al. Primary lung involvement in Waldenström’s macroglobulinaemia: report of two cases and review of the literature. Acta Haematol 2001; 105:92–6.
81. Kaila VL, el Newihi HM, Dreiling BJ, Lynch CA, Mihas AA. Waldenström’s macroglobulinemia of the stomach presenting with upper gastrointestinal hemorrhage. Gastrointest Endosc 1996; 44:73–5.
82. Yasui O, Tukamoto F, Sasaki N, Saito T, Yagisawa H, Uno A, Nanjo H. Malignant lymphoma of the transverse colon associated with macroglobulinemia. Am J Gastroenterol 1997; 92:2299–301.
83. Rosenthal JA, Curran WJ Jr, Schuster SJ. Waldenström’s macroglobulinemia resulting from localized gastric lymphoplasmacytoid lymphoma. Am J Hematol 1998; 58:244–5.
84. Recine MA, Perez MT, Cabello-Inchausti B, Lilenbaum RC, Robinson MJ. Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting as small intestinal obstruction. Arch Pathol Lab Med 2001; 125:677–9.
85. Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA. Renal disease in Waldenström’s macroglobulinaemia. Nephrol Dial Transplant 1997; 12:1256–9.
86. Moore DF Jr, Moulopoulos LA, Dimopoulos MA. Waldenström macroglobulinemia presenting as a renal or perirenal mass: clinical and radiographic features. Leuk Lymphoma 1995; 17:331–4.
87. Mascaro JM, Montserrat E, Estrach T, Feliu E, Ferrando J, Castel T, et al. Specific cutaneous manifestations of Waldenström’s macroglobulinaemia. A report of two cases. Br J Dermatol 1982; 106:17–22.
88. Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM: Maladie de Waldenström? Bull Soc Fr Dermatol Syphiligr 1974; 81:363–8.
89. Roux S, Fermand JP, Brechignac S, Mariette X, Kahn MF, Brouet JC. Tumoral joint involvement in multiple myeloma and Waldenström’s macroglobulinemia – report of 4 cases. J Rheumatol 1996; 23:2175–8.
90. Orellana J, Friedman AH. Ocular manifestations of multiple myeloma, Waldenström’s macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol 1981; 26:157–69.
91. Ettl AR, Birbamer GG, Philipp W. Orbital involvement in Waldenström’s macroglobulinemia: ultrasound, computed tomography and magnetic resonance findings. Ophthalmologica 1992; 205:40–5.
92. Civit T, Coulbois S, Baylac F, Taillandier L, Auque J. [Waldenström’s macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and Neel syndrome. Apropos of a new case.] Neurochirurgie 1997; 43:245–9.
93. McMullin MF, Wilkin HJ, Elder E. Inaccurate haemoglobin estimation in Waldenström’s macroglobulinaemia. J Clin Pathol 1995; 48:787.
94. Treon SP, Branagan AR, Hunter Z, Ditzel Santos D, Tournilhac O, Hatjiharissi E, Xu L, and Manning R. IgA and IgG hypogammaglobulinemia persists in most patients with Waldenstrom’s macroglobulinemia despite therapeutic responses, including complete remissions. Blood 2004; 104: 306b.
95. Treon SP, Hunter Z, Ciccarelli BT, et al. IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom’s Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID) Blood 2008; 112: 3749.
96. Dutcher TF, Fahey JL. The histopathology of macroglobulinemia of Waldenström. J Natl Cancer Inst 1959; 22:887–917.
97. Moulopoulos LA, Dimopoulos MA, Varma DG, Manning JT, Johnston DA, Leeds NE, et al. Waldenström macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvis. Radiology 1993; 188:669–73.
98. Gobbi PG, Bettini R, Montecucco C, Cavanna L, Morandi S, Pieresca C, et al. Study of prognosis in Waldenström’s macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83:2939–45.
99. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852–8.
100. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM,   et al. Prognostic factors and response to fludarabine therapy in patients with    Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41–8.
101. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström’s macroglobulinemia. Semin Oncol 2003; 30:116–120.
102. Dimopoulos M, Gika D, Zervas K, et al. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom’s macroglobulinemia. Leuk Lymph 2004; 45: 1809-13.
103. Anagnostopoulos A, Zervas K, Kyrtsonis M, et al. Prognostic value of serum beta 2-microglobulin in patients with Waldenstrom’s macroglobulinemia requiring therapy. Clin Lymph Myeloma 2006; 7: 205-9.
104. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom’s macroglobulinemia. Blood 2009; in press.
105. Leleu XP, Manning R, Soumerai JD, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27: 250-5.
106. Gertz M, Anagnostopoulos A, Anderson KC, et al. Treatment recommendations in Waldenström’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström’s macroglobulinemia. Semin Oncol 2003; 30:121–6.
107. Treon SP, Gertz MA, Dimopoulos MA, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Blood 2006; 107:3442-6.
108. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27: 120-6.
109. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al. Waldenström’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108:737–42.
110. Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobulinemia. Blood 1994; 83:1452-9.
111. Petrucci MT, Avvisati G, Tribalto M, Giovangrossi P, Mandelli F. Waldenström’s macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989; 226:443–7.
112. Case DC Jr, Ervin TJ, Boyd MA, Redfield DL. Waldenström’s macroglobulinemia: long-term results with the M-2 protocol. Cancer Invest 1991; 9:1–7.
113. Facon T, Brouillard M, Duhamel A, Morel P, Simon M, Jouet JP, et al. Prognostic factors in Waldenström’s macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553–8.
114. Dimopoulos MA, Kantarjian H, Weber D, O’Brien S, Estey E, Delasalle K, et al. Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12:2694–8.
115. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenström’s macroglobulinaemia. Nouv Rev Fr Hematol 1994; 36:317–20.
116. Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström’s disease with cladribine. Arbeitsgemeinschaft Medikamentose Tumortherapie. Ann Hematol 1997; 74:7–10.
117. Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol 1998; 103:690–5.
118. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström’s macroglobulinemia. Eur J Haematol 1999; 63:35–41.
119. Betticher DC, Hsu Schmitz SF, Ratschiller D, von Rohr A, Egger T, Pugin P, et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström’s macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 1997; 99:358–63.
120. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenström’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6:49–52.
121. Dimopoulos MA, O’Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, et al. Fludarabine therapy in Waldenström’s macroglobulinemia. Am J Med 1993; 95:49–52.
122. Foran JM, Rohatiner AZ, Coiffier B, Barbui T, Johnson SA, Hiddemann W, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17:546–53.
123. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, Chott A, Gisslinger H, Knobl P, et al. Fludarabine therapy in Waldenström’s macroglobulinemia. Ann Hematol 2000; 79:556–9.
124. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41–8.
125. Zinzani PL, Gherlinzoni F, Bendandi M, Zaccaria A, Aitini E, Salvucci M, et al. Fludarabine treatment in resistant Waldenström’s macroglobulinemia. Eur J Haematol 1995; 54:120–3.
126. Leblond V, Ben Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, et al. Activity of fludarabine in previously treated Waldenström’s macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol 1998; 16:2060–4.
127. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2-Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol 1994; 5:288–9.
128. Lewandowski K, Halaburda K, Hellmann A. Fludarabine therapy in Waldenström’s macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine. Leuk Lymphoma 2002; 43:361–3.
129. Thomas S, Hosing C, Delasalle KB, et al. Success rates of autologous stem cell collection in patients with Waldenstrom’s macroglobulinemia. Proc 5^th International Workshop on Waldenstrom’s macroglobulinemia 2008 (Supplemental Abstract).
130. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenstrom’s macroglobulinemia patients with nucleoside analogue based therapy. Clin Lymph Myeloma 2009; in press.
131. Treon SP, Kelliher A, Keele B, et al: Expression of serotherapy target antigens in Waldenstrom’s macroglobulinemia: Therapeutic applications and considerations. Semin Oncol 2003; 30:248-52.
132. Treon SP, Shima Y, Preffer FI, et al: Treatment of plasma cell dyscrasias with antibody-mediated immunotherapy. Semin Oncol 1999; 26 (Suppl 14):97-106.
133. Byrd JC, White CA, Link B, et al: Rituximab therapy in Waldenstrom’s macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:1525-7.
134. Weber DM, Gavino M, Huh Y, et al: Phenotypic and clinical evidence supports rituximab for Waldenstrom’s macroglobulinemia. Blood 1999; 94:125a.
135. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-24.
136. Treon SP, Agus DB, Link B, et al: CD20-Directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemia. J Immunother 2001; 24:272-79.
137. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) Leuk Lymphoma 45:2047-2055, 2004.
138. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenstrom’s macroglobulinemia with rituximab. J Clin Oncol 2002; 20:2327-33.
139. Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR. Extended rituximab therapy in Waldenström’s Macroglobulinemia. Ann Oncol 2005; 16:132-8.
140. Donnelly GB, Bober-Sorcinelli K, Jacobson R, Portlock CS. Abrupt IgM rise following treatment with rituximab in patients with Waldenstrom’s macroglobulinemia. Blood 2001; 98:240b.
141. Treon SP, Branagan AR, Anderson KC. Paradoxical increases in serum IgM levels and serum viscosity following rituximab therapy in patients with Waldenstrom’s macroglobulinemia. Blood 2003; 102:690a.
142. Ghobrial IM, Fonseca R, Greipp PR, et al: The initial “flare” of IgM level after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia: An Eastern Cooperative Oncology Group Study. Blood 2003; 102:448α.
143. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al. Predictive factors for response to rituximab in Waldenstrom’s macroglobulinemia. Clin Lymphoma 2005; 5:270-2.
144. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgRIIIA (CD16) receptor expression are associated with clinical responses to Rituximab in Waldenstrom’s Macroglobulinemia. J Clin Oncol 2005; 23: 474-81.
145. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin Oncol 30:243-247, 2003.
146. Treon SP, Branagan AR, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenstrom’s macroglobulinemia. Blood 2009; Epub ahead of print.
147. Tam CS, Wolf MM, Westerman D, et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 2005; 6:136-9.
148. Hensel M, Villalobos M, Kornacker M, et al. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005; 6:131-5.
149. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom’s macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide. J Clin Oncol 2007; 25:3344-9.
150. Buske C, Hoster E, Dreyling MH, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23: 153-61.
151. Treon SP, Hunter Z, Branagan A. CHOP plus rituximab therapy in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2005; 5: 273-7.
152. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom’s macroglobulinemia. Clin Lymph Myeloma 2009; in press.
153. Dimopoulos MA, Hamilos G, Efstathiou E, et al: Treatment of Waldenstrom’s macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 44:993-996, 2003.
154. Tamburini J, Levy V, Chateilex C, et al. Fludarabine plus cyclophosphamide in Waldenstrom’s macroglobulinemia: results in 49 patients. Leukemia 2005; 19:1831-4.
155. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-83.
156. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-62.
157. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Preliminary results of an IFM Phase II Study. Blood 2004; 104:416a.
158. Mitsiades CS, Mitsiades N, McMullan CJ, et al. The proteasome inhibitor bortezomib (PS-341) is active against Waldenstrom’s macroglobulinemia. Blood 2003; 102:181a.
159. Treon SP, Hunter ZR, Matous J, et al. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom’s macroglobulinemia: Results of WMCTG Trial 03-248.  Clin Cancer Res 2007; 13:3320-5.
160. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1570-5.
161. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica 2005; 90:1655-7.
162. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin 2005; 23:657-8.
163. Treon SP, Ioakimidis L, Soumerai JD, et al.
     Primary Therapy of Waldenstrom’s Macroglobulinemia with Bortezomib, Dexamethasone and Rituximab. J Clin Oncol 2009; in press.
164. Ghobrial IM, Matous J, Padmanabhan S, et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom’s Macroglobulinemia. Blood 112; 832.
165. Agathocleous A, Rule S, Johson P. Prelimanry results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab in patients with follicular lymphoma, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. Blood 2007; 110: 754a.
166. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymph Myeloma 2006; 6: 478-83.
167. Hunter ZR, Boxer M, Kahl B, et al. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. Proc Am Soc Clin Oncol 2006; 24: 427s.
168. Owen RG, Rawstron AC, Osterborg A, Lundin J, Svensson G, Hillmen P. Activity of alemtuzumab in relapsed/refractory Waldenstrom's macroglobulinemia. Blood 2003; 102: 644a.
169. Dimopoulos MA, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, et al. Treatment of Waldenström’s macroglobulinemia with thalidomide. J Clin Oncol 2001; 19:3596–601.
170. Coleman C, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenström’s macroglobulinemia with clarithromycin, low-dose thalidomide and dexamethasone. Semin Oncol 30:270–4.
171. Dimopoulos MA, Zomas K, Tsatalas K, Hamilos G, Efstathiou E, Gika D, et al. Treatment of Waldenström’s macroglobulinemia with single agent thalidomide or with combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30:265–9.
172. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol 2005; 128:192-203.
173. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
174. Janakiraman N, McLaughlin P, White CA, et al: Rituximab: Correlation between effector cells and clinical activity in NHL. Blood 92:337a, 1998.
175. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom’s Macroglobulinemia. Blood 2008; 112: 4452-7.
176. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenström’s Macroglobulinemia. Clin Cancer Res 2008; 15: 355-60.
177. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström’s macroglobulinaemia. Br J Haematol 1999; 105:993–6.
178. Munshi NC, Barlogie B. Role for high dose therapy with autologous hematopoietic stem cell support in Waldenström’s macroglobulinemia. Semin Oncol 2003; 30:282–5.
179. Dreger P, Glass B, Kuse R, Sonnen R, von Neuhoff N, Bolouri H, et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström’s macroglobulinaemia. Br J Haematol 1999; 106:115–18.
180. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenström’s macroglobulinemia. Bone Marrow Transplant 2001; 27:1027–9.
181. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Colombat P, Milpied N, et al. Transplantation in Waldenström’s macroglobulinemia – the French Experience. Semin Oncol 2003; 30:291–6.
182. Anagnostopoulos A, Hari PN, Perez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-54.
183. Kyriakou H, on behalf of the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Haematopoietic stem cell transplantation for Waldenstrom’s macroglobulinemia. Proceedings of the 5^th International Workshop on Waldenstrom’s macroglobulinemia, Stockholm, Sweden 2008 (Abstract 146).
184. Maloney D. Evidence for GVWM following mini-allo in Waldenstrom’s macroglobulinemia. Proceedings of the 5^th International Workshop on Waldenstrom’s macroglobulinemia, Stockholm, Sweden 2008 (Abstract 147).
185. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.  Semin Oncol 2003; 30:127-31.
186. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma Myeloma 2006; 6:380-3.
187. Nichols GL, Savage DG. Timing of Rituximab/Fludarabine in Waldenstrom’s macroglobulinemia may avert hyperviscosity. Blood 2004; 104:237b.
188. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105-12.
189. Owen R. Complexities of assessing response in Waldenstrom’s macroglobulinemia. Proceedings of the 5^th International Workshop on Waldenstrom’s macroglobulinemia, Stockholm, Sweden 2008 (Abstract 128).
190. Ciccarelli BT, Yang G, Hatjiharissi E, et al. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab induced IgM flare, as well as plasmapheresis in patients with Waldenstrom’s macroglobulinemia. Clin Lymph Myeloma 2009; in press.